POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte.

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
STATISTICS HYPOTHESES TEST (I)
STATISTICS INTERVAL ESTIMATION Professor Ke-Sheng Cheng Department of Bioenvironmental Systems Engineering National Taiwan University.
STATISTICS POINT ESTIMATION Professor Ke-Sheng Cheng Department of Bioenvironmental Systems Engineering National Taiwan University.
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
Design of Dose Response Clinical Trials
NTDB ® Annual Report 2009 © American College of Surgeons All Rights Reserved Worldwide Percent of Hospitals Submitting Data to NTDB by State and.
CALENDAR.
FACTORING ax2 + bx + c Think “unfoil” Work down, Show all steps.
HEPATIC CLEARANCE Q x CA Q x CV Q(CA - CV) 1. Mass Balance
1 From the analytical uncertainty to uncertainty in data interpretation D. Concordet, J.P. Braun
Chapter 7 Sampling and Sampling Distributions
1 Exercise 14 Dose titration and selection of a therapeutic dose for a new quinolone in pigs.
A Fractional Order (Proportional and Derivative) Motion Controller Design for A Class of Second-order Systems Center for Self-Organizing Intelligent.
Elementary Statistics
RANDOMIZED CONTROLLED TRIAL
Look at This PowerPoint for help on you times tables
Scottish Intensive Care Society Audit Group, Annual Report Note from Scottish Intensive Care Society Audit Group.
Monte Carlo simulations and bioequivalence of antimicrobial drugs NATIONAL VETERINARY S C H O O L T O U L O U S E July 2005 Didier Concordet.
Gentamicin – principles of use and monitoring September 2013 Dr Robert Jackson.
When you see… Find the zeros You think….
Research Summary 08/2010 Dr. Andrej Mošat` Prof. A. Linninger, Laboratory for Product and Process Design, M/C 063 University of Illinois at Chicago 04.
& dding ubtracting ractions.
Physics for Scientists & Engineers, 3rd Edition
9. Two Functions of Two Random Variables
Azithromycin Pharmacokinetics in Pregnancy James H. Fischer, Pharm.D., FCCP May 17, 2011.
Procalcitonin Over the past two decades, the body of literature on the clinical usefulness of procalcitonin (PCT) in adults has grown rapidly. Although.
Severe Sepsis Initial recognition and resuscitation
Address for contact: FT Musuamba - Department of Clinical Biochemistry, Department of Pharmacokinetics, Metabolism, and Toxicology Av Hippocrate 10, B-1200.
CREATININE AND CYSTATIN-C BASED GFRs VS 51 Cr-EDTA GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS 1 4th Department of Internal Medicine, Hippokration General.
Pharmacotherapy in the Elderly Judy Wong
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
A seminar on ALTERED KINETICS IN RENAL DISEASES BY A.SRILATHA (M.Pharm I sem ) Department of Pharmaceutics BLUE BIRDS COLLEGE OF PHARMACY (Affiliated to.
Figure 1. Diagnostic plots for propofol pharmacokinetics and effect (BIS) in morbidly obese patients including observations versus individual- predictions.
Dose Adjustment in Renal and Hepatic Disease
PRESENTER: HALIMATUL NADIA M HASHIM SUPERVISOR: DR NIK AZMAN NIK ADIB.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Results: In the presence of PD measurements, PK data provided little additional information. By a limited PD sampling the number of patients on target.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
Multiple dosing: intravenous bolus administration
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Model-based dose selection for next dose- finding trial 1. Introduction Exploratory clinical development trials often include biomarkers or clinical readout.
Introduction: Temocillin (TMO) is a narrow spectrum penicillin with good activity against Gram negative micro-organisms including ESBL and AmpC producers.
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Pk/Pd modelling : Clinical Implications
INTERMITTENT IV VANCOMYCIN WHAT DOSE SHOULD WE START WITH?
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Adequacy of beta-lactam antibiotic dosing in critically ill children on continuous renal replacement therapy: A pilot study. Diaz F 1,2, Benner KW 3, Sewell.
Background and Objectives Methods
Identification of optimal dose and dosing regimen of clofazimine for the treatment of multi-drug resistant tuberculosis (MDR-TB) based on pharmacokinetic.
LIPOPHILIC AND PROTEIN BOUND ANTIBIOTICS ARE MORE LIKELY TO HAVE ALTERED PHARMACOKINETCIS DURING ECMO Kiran Shekar, Jason Roberts, Sara Diab, Adrian Barnett,
Pharmacokinetics of Vancomycin in Adult Oncology Patients
The aminoglycoside antibiotics
Drug Therapy in Geriatric Patients
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
Pharmcokinetics Allie punke.
Background and Objectives
Clinical Pharmacokinetics
Volume 27, Issue 1, Pages (January 2011)
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
Therapeutic Drug Monitoring chapter 1 part 1
Presentation transcript:

POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte (4), H. Blasco (1), PF Dequin (3). (1) Department of clinical pharmacology, University hospital, Tours, France. (2) Department of clinical pharmacology, Université de la méditerranée, APHM, Marseilles, France. (3) Intensive acre unit, University hospital, Tours, France. (4) Laboratory of microbiology, University hospital, Tours, France Introduction Patients and Methods Résults Pharmacokinetics of drugs used in critically ill patients may be altered because of renal or hepatic dysfunction, variation of vascular permeability, abnormal fluid balance, altered protein metabolism and low albumin. Ceftriaxone is a third generation cephalosporin with a broad spectrum activity against gram- positive and gram-negative bacteria. As a time-dependant antibiotic, the pharmacokinetic- pharmacodynamic parameter determining its in vivo efficacy is the time that serum levels exceeds 4xMIC. Although commonly used, there are few data on its pharmacokinetics in critically ill patients. We found a wide inter-patient but weak intrapatient variability of ceftriaxone PK. The only parameter that influenced ceftriaxone pharmacokinetics was CLcr, but only when CLcr was > 60 ml/min, suggesting participation of non-renal phenomenon. Simulations indicated that the risk of being under 4 MIC for the entire dosing interval is very low and exists only in patient with high glomerular filtration rate (CLcr > 120 ml/min). Objectives Conclusion Prospective population pharmacokinetic study in patients receiving ceftriaxone (1 or 2 g once a day). MIC of bacterial isolates to ceftriaxone was determined by the E-test method A pharmacokinetic (PK) profile was obtained on two occasions for each patient. First PK on the second day of ceftriaxone therapy Second PK after the resolution of sepsis. Population pharmacokinetic analysis was performed using NONMEM VI. Fourteen potential covariates were evaluated, including demographic, biological and clinical characteristics, and co-administered drugs. Between Occasion Variability (BOV) was analyzed from PK1 to PK2. Precision and stability of parameter estimates were evaluated by non-parametric bootstrap procedure. Simulations were made at various doses for hypothetical patients having different covariate values and concentrations were compared to MICs of common ICU pathogens. To describe population pharmacokinetics of ceftriaxone in a large group of critically ill patients suffering from sepsis, severe sepsis or septic shock To investigate the influence of several clinical and biological covariates on pharmacokinetic parameters To simulate various dosing regimen to evaluate whether some of them could produce concentrations below the MIC of common ICU pathogens. The model did not supported BOV on any parameter. The other PK parameters were V2 (7.35 L; rse=10.2%; CV=65%) and intercompartment clearance (5.28 h-1; fixed). Residual variability modelled as proportional was 24%. The VPCs obtained with the final model are shown below: CL=THETA(1)+THETA(2)*(CLcr/4.26) THETA (1)=0.56; rse=19.6 THETA(2)= 0.32; rse=37.5 Simulations performed for 2 different ceftriaxone doses and 4 different renal functions indicated that most patients will achieve effective concentrations, even with a dose of 1 g. Covariate analysis showed that V1 increased with more severe type of sepsis (V1 = 8.21 ± 3.55 L, 9.77 ± 3.83 L and 11.5 ± 4.16 L for sepsis, severe sepsis and septic shock, respectively) but its inclusion in the model was not significant. Ceftriaxone CL was independent of CLcr for values below 60 ml/min and then increased linearly with GFR We included 54 patients: 19 suffered from sepsis, 9 from severe sepsis and 26 from septic shock. Eleven patients were hemofiltrated or haemodyalized. For the others, creatinine clearance (CLcr) ranged 5.5 to 214 ml/min. Renal function improved from PK1 to PK2 with median (range) values of 63 ( ) and 70 ( ) mL/min, respectively. A 2-compartment pharmacokinetic model was selected CLcr = 30 ml/mn CLcr = 180 ml/mn